Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Antoine Abou Rached, Selim Abou Kheir, Jowana Saba, Salwa Assaf, Georges Kassis, Yuri Sanchez Gonzalez & Olivier Ethgen. (2018) Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment. Hepatic Medicine: Evidence and Research 10, pages 73-85.
Read now
Read now
Articles from other publishers (12)
Zahra Goudarzi, Abdollah Poursamad, Iman Karimzadeh, Nahid Jallaly, Khosro Keshavarz & Seyed Moayed Alavian. (2021) Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C. Hepatitis Monthly 21:8.
Crossref
Crossref
Riichiro Suenaga, Machi Suka, Tomohiro Hirao, Isao Hidaka, Isao Sakaida & Haku Ishida. (2021) Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages. PLOS ONE 16:4, pages e0248748.
Crossref
Crossref
Ong The Due, Ammarin Thakkinstian, Montarat Thavorncharoensap, Abhasnee Sobhonslidsuk, Olivia Wu, Nguyen Khanh Phuong & Usa Chaikledkaew. (2020) Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam. Value in Health 23:9, pages 1180-1190.
Crossref
Crossref
Kota Nagai, Kazuki Ide, Yohei Kawasaki, Sachiko Tanaka‐Mizuno, Kahori Seto, Shinji Iwane, Yuichiro Eguchi & Koji Kawakami. (2020) Estimating the cost‐effectiveness of screening for hepatitis C virus infection in Japan. Hepatology Research 50:5, pages 542-556.
Crossref
Crossref
Yueran Zhuo, Tomoyuki Hayashi, Qiushi Chen, Rakesh Aggarwal, Yvan Hutin & Jagpreet Chhatwal. (2020) Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan. Scientific Reports 10:1.
Crossref
Crossref
Haruhisa Fukuda, Yoshihiko Yano, Daisuke Sato, Sachiko Ohde, Shinichi Noto, Ryo Watanabe & Osamu Takahashi. (2019) Healthcare Expenditures for the Treatment of Patients Infected with Hepatitis C Virus in Japan. PharmacoEconomics 38:3, pages 297-306.
Crossref
Crossref
Yu‐Jun Wong, McVin HH Cheen, John C Hsiang, Rahul Kumar, Jessica Tan, Eng K Teo & Prem H Thurairajah. (2019) Economic evaluation of direct‐acting antivirals for the treatment of genotype 3 hepatitis C infection in Singapore. JGH Open 3:3, pages 210-216.
Crossref
Crossref
László Szilberhorn, Zoltán Kaló & Tamás Ágh. (2018) Cost-Effectiveness of Second-generation Direct-acting Antiviral Agents in Chronic HCV Infection: A Systematic Literature Review. Antiviral Therapy 24:4, pages 247-259.
Crossref
Crossref
Z. M. Younossi, A. Tanaka, Y. Eguchi, L. Henry, R. Beckerman & M. Mizokami. (2018) Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. Journal of Viral Hepatitis 25:8, pages 945-951.
Crossref
Crossref
Lauren E. Cipriano & Jeremy D. Goldhaber-Fiebert. (2018) Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy & Practice 3:1, pages 238146831877663.
Crossref
Crossref
Maria Stepanova & Zobair M. Younossi. (2017) Economic Burden of Hepatitis C Infection. Clinics in Liver Disease 21:3, pages 579-594.
Crossref
Crossref
Zobair M. Younossi, Atsushi Tanaka, Yuichiro Eguchi, Young‐Suk Lim, Ming‐Lung Yu, Norifumi Kawada, Yock Young Dan, Craig Brooks‐Rooney, Francesco Negro & Mario U. Mondelli. (2016) The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver International 37:2, pages 159-172.
Crossref
Crossref